Abstract #0246

MR Spectroscopy as a Biomarker to Predict the Responses of Glioblastoma to an Anti-Angiogenic Treatment

Heisoog Kim¹, Ciprian Catana¹, Eva-Maria Ratai¹, Ovidiu C. Andronesi¹, Tracy T. Batchelor², Rakesh K. Jain³, A. Gregory Sorensen¹

¹Radiology, A. A. Martinos Center, Charlestown, MA, USA; ²Neurology, Massachusetts General Hospital, Boston, MA, USA; ³Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

In this study, the changes of predominant metabolites in recurrent glioblastoma (rGBM) were evaluated for predicting tumor responses to an anti-angiogenic treatment. While thirty-one rGBM patients were treated with daily doses of cediranib, chemical shift imaging data were acquired serially at the specific time points of treatment. We measured the concentrations of N-acetyl aspartate (NAA) and choline (Cho) normalized by creatine in normal tissue (norCre) in enhancing tumor by categorizing two different survival groups. Notably, NAA/Cho showed a high prediction to 6-month overall survival in ROC analysis. These observations have important implications for treatment management.